Safety of Lenalidomide (LEN) 10mg in Non-Del(5q) Versus Del(5q) in the Treatment of Patients (Pts) with Lower-Risk Myelodysplastic Syndromes (MDS): Pooled Analysis of Treatment-Emergent Adverse Events (TEAEs)

被引：0
|
作者：
Almeida, Antonio [1 ]
Santini, Valeria [2 ]
Croepper, Stefanie [3 ]
Jonasova, Anna [4 ]
Vey, Norbert [5 ]
Giagounidis, Aristoteles [3 ]
Hellstrom-Lindberg, Eva [6 ]
Mufti, Ghulam J. [7 ]
Sanz, Guillermo [8 ]
Skikne, Barry [9 ]
Hoenekopp, Albert [10 ]
Seguy, Francis [10 ]
Zhong, Jianhua [9 ]
Fenaux, Pierre [11 ]
机构：
[1] Inst Portugues Oncol Francisco Gentil, Lisbon, Portugal
[2] Univ Florence, AOU Careggi, Florence, Italy
[3] Marien Hosp, Dusseldorf, Germany
[4] Charles Univ Prague, Gen Hosp, Dept Med 1, Prague, Czech Republic
[5] Ctr Reg Lutte Canc, Inst Paoli Calmettes, Marseille, France
[6] Karolinska Univ Hosp, Stockholm, Sweden
[7] Kings Coll Hosp London, London, England
[8] Hosp Univ Politecn La Fe, Valencia, Spain
[9] Celgene Corp, Summit, NJ USA
[10] Celgene Int, Boudry, Switzerland
[11] Univ Paris 07, Hop St Louis, Serv Hematol Seniors, Paris, France
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
10.1182/blood.V126.23.2880.2880
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [2] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Fenaux, Pierre
    Gatterman, Norbert
    Ozawa, Keiya
    Goldberg, Stuart L.
    Weaver, Jerry
    Sugrue, Mary M.
    BLOOD, 2016, 128 (22)
  • [3] Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)
    Almeida, Antonio
    Fenaux, Pierre
    List, Alan F.
    Raza, Azra
    Platzbecker, Uwe
    Santini, Valeria
    LEUKEMIA RESEARCH, 2017, 52 : 50 - 57
  • [4] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [5] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Haferlach, Torsten
    Zhong, Jim
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    MacBeth, Kyle J.
    Almeida, Antonio
    LEUKEMIA, 2021, 35 (03) : 897 - 900
  • [6] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Valeria Santini
    Pierre Fenaux
    Aristoteles Giagounidis
    Uwe Platzbecker
    Alan F. List
    Torsten Haferlach
    Jim Zhong
    Chengqing Wu
    Konstantinos Mavrommatis
    C. L. Beach
    Kyle J. MacBeth
    Antonio Almeida
    Leukemia, 2021, 35 : 897 - 900
  • [7] Treatment-emergent adverse events (TEAEs) in lenalidomide (LEN)-treated Low-/Int-l-risk myelodysplastic syndromes (MDS) patients (pts) without del(5q) ineligible for or refractory to erythropoiesis-stimulating agents (ESAs).
    Almeida, Antonio Medina
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Giagounidis, Aristoteles
    Goldberg, Stuart
    Gropper, Stefanie
    Jonasova, Anna
    Mufti, Ghulam J.
    Sanz, Guillermo F.
    Vey, Norbert
    Castaneda, Carmen
    Zhong, Jianhua
    Beach, C. L.
    Santini, Valeria
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [9] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan F.
    Selleslag, Dominik
    Mittelman, Moshe
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Li, Jack Shiansong
    Sugrue, Mary M.
    Fenaux, Pierre
    BLOOD CANCER JOURNAL, 2018, 8
  • [10] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Mikkael A. Sekeres
    Arlene S. Swern
    Aristoteles Giagounidis
    Alan F. List
    Dominik Selleslag
    Moshe Mittelman
    Brigitte Schlegelberger
    Gudrun Göhring
    Jack Shiansong Li
    Mary M. Sugrue
    Pierre Fenaux
    Blood Cancer Journal, 8
12345